AstraZeneca spins out antibiotics R&D
This article was originally published in Scrip
AstraZeneca is to spin out its early-stage small molecule antibiotics pipeline into a standalone subsidiary, into which it will invest $40m. The new company is expected to be led by and include staff from AstraZeneca's Innovative Medicines Unit. Some 95 staff in Waltham, Massachusetts will be affected; they are likely to take up positions at the new company or move to other parts of AZ.